Synageva, Mitsubishi extend deal on protein drugs for rare disease

04/4/2012 | Genetic Engineering & Biotechnology News

Mitsubishi Tanabe Pharma and Synageva BioPharma will jointly develop a second therapeutic protein for an orphan disease using the latter's protein expression platform as part of their expanded rare-disease deal. Synageva will receive $9 million in upfront fees and reimbursement for development costs, plus potential milestone payments and sales royalties.

View Full Article in:

Genetic Engineering & Biotechnology News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Regional Director, Southeastern Region - State Affairs
America's Health Insurance Plans (AHIP)
Washington, DC
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Multiple Locations, SL_Multiple Locations
Market Intelligence Manager
Olympus Corporation of the Americas
Southborough, MA